Working... Menu
Trial record 77 of 183 for:    Foradil Combi OR symbicort OR (Budesonide AND formeterol)

A Study to Investigate the Differential Effects of Inhaled Symbicort and Advair on Lung Microbiota (DISARM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02833480
Recruitment Status : Recruiting
First Posted : July 14, 2016
Last Update Posted : May 13, 2019
Information provided by (Responsible Party):
Don Sin, University of British Columbia

Brief Summary:
This study will evaluate the effects of budesonide (using Symbicort which is budesonide and formoterol) and fluticasone (using Advair which is fluticasone and salmeterol) on the airway microorganisms of patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). This is a randomized, parallel group, two-centered clinical trial study to evaluate the effects of a 12 week treatment with Symbicort 400 mcg BID and Advair 250 mcg BID (via Diskus) on airway microbiota in patients with moderate-to-severe COPD. The control arm of this study will be Oxeze 12 ug BID.

Condition or disease Intervention/treatment Phase
Chronic Obstructive Pulmonary Disease Drug: Fluticasone group Drug: Budesonide group Drug: Formoterol group Phase 2

Detailed Description:

This is a randomized, non-placebo controlled study to evaluate the effects of Symbicort 400 mcg twice daily (BID) and Advair 250 mcg BID over 12 weeks. As the standard of therapy for COPD is a long-acting muscarinic antagonist (LAMA) treatment, a placebo only group cannot be ethically justified. The control arm of this study will thus be Oxeze 12 ug BID. The study will recruit approximately 69 subjects, from St. Paul's Hospital and British Columbia Cancer Agency, randomized 1:1:1 to the 3 arms in blocks. We anticipate 10 to 15% drop out rate, which will enable approximately 60 subjects for full analysis.

After the initial enrolment and confirmation of the entry criteria, subjects will perform spirometry before and following bronchodilation with salbutamol (up to 400 ug). They will then enter a 4-week run-in period during which all subjects will be withdrawn from inhaled corticosteroid containing products. They will then be treated with formoterol via Turbuhaler 12 ug BID and short-acting beta-2 agonists as needed (PRN). Subjects may also have LAMA (either tiotropium 18 ug once daily or glycopyrronium 50 ug once daily) at the discretion of the attending physician. At the end of the run-in phase, eligibility will be confirmed and then subjects will undergo pre and post-spirometry, low-dose thoracic computed tomography (CT) and bronchoscopy. One week post-bronchoscopy, the subjects will be randomized to a 12-week treatment period. Subjects may also have LAMA at the discretion of the attending physician. At the end of the 12 week treatment period, the subjects will undergo pre- and post-spirometry and 2nd bronchoscopy. The subjects will be re-evaluated one week following bronchoscopy and then discharged from the study. All subjects with pulmonary nodule requiring follow-up will be evaluated by the attending physician and the pulmonary nodule will be investigated as per guidelines of the Fleischner Society.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 69 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Study to Investigate the Differential Effects of Inhaled Symbicort and Advair on Lung Microbiota
Study Start Date : February 2015
Estimated Primary Completion Date : January 2020
Estimated Study Completion Date : June 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Fluticasone group
Advair (fluticasone) 250 mcg to be administered twice daily via Diskus for 12 weeks
Drug: Fluticasone group
Other Name: Advair

Experimental: Budesonide group
Symbicort (budesonide) 400 mcg to be administered twice daily via Turbuhaler for 12 weeks
Drug: Budesonide group
Other Name: Symbicort

Active Comparator: Formoterol group
Oxeze (formoterol) 12 microg to be administered twice daily via Turbuhaler for 12 weeks
Drug: Formoterol group
Other Name: Oxeze

Primary Outcome Measures :
  1. Change in total bacterial population in the bronchoalveolar lavage fluid [ Time Frame: 12 weeks ]
  2. Change in bacterial diversity using Shannon Index based on 16S sequencing. [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. Change in bacterial membership using Beta-diversity [ Time Frame: 12 weeks ]
  2. Characterization of bacteria Operational Taxonomic Unit [ Time Frame: 12 weeks ]
  3. Change in total cell count in bronchoalveolar lavage fluid [ Time Frame: 12 weeks ]
  4. Change in total neutrophil count in bronchoalveolar lavage fluid [ Time Frame: 12 weeks ]
  5. Change in total lymphocyte count in bronchoalveolar lavage fluid [ Time Frame: 12 weeks ]
  6. Change in total mono-macrophage count in bronchoalveolar lavage fluid [ Time Frame: 12 weeks ]
  7. Change in St. George's Respiratory Questionnaire [ Time Frame: 12 weeks ]
  8. Change in forced expiratory volume in 1 second [ Time Frame: 12 weeks ]
  9. Change in forced vital capacity [ Time Frame: 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Provision of informed consent prior to any study specific procedures.
  • History of moderate to very severe COPD with a post-bronchodilator forced expiratory volume/forced vital capacity (FEV1/FVC) <0.70 and a post-bronchodilator FEV1>20% and ≤80% of predicted normal value at screening.
  • Current smoker or ex-smoker with a tobacco history of ≥10 pack-years (1 pack year= 20 cigarettes smoked per day for 1 year).

Exclusion Criteria:

  • Clinically important pulmonary disease other than COPD (e.g. active lung infection, clinically significant bronchiectasis, pulmonary fibrosis, cystic fibrosis, hypoventilation syndrome associated with obesity, and primary ciliary dyskinesia) and/ or radiological findings suggestive of a respiratory disease other than COPD that is contributing to the subject's respiratory symptoms.
  • Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could:

    1. Affect the safety of the subject throughout the study
    2. Influence the findings of the study or their interpretation
    3. Impede the subject's ability to complete the entire duration of study Subjects who have epilepsy must be on a stable dose of medication for 30 days prior to Visit 4.
  • Unstable ischemic heart disease, or uncontrolled arrhythmia, cardiomyopathy, heart failure, and renal failure, or uncontrolled hypertension as defined by the Investigator, or any other relevant cardiovascular disorder as judged by the Investigator
  • Treatment with systemic corticosteroids and/or antibiotics, and/or hospitalization for a COPD exacerbation within 8 weeks prior to enrolment (Visit 1), based on last dose of steroids or last date of hospitalization whatever occurred later.
  • Acute upper or lower respiratory infection requiring antibiotics or antiviral medication within 2 weeks prior to enrolment (Visit 1).
  • Pneumonia within 8 weeks prior to enrolment (Visit 1), based on the last day of antibiotic treatment or hospitalization date, whatever occurred later.
  • Pregnant, breastfeeding, or lactating women.
  • Any clinically significant abnormal findings in physical examination, vital signs, haematology, clinical chemistry, or urinalysis during screening/run-in period, which, in the opinion of the Investigator, may put the subject at risk because of his/her participation in the study, or may influence the results of the study, or the subject's ability to complete entire duration of the study.
  • Use of immunosuppressive medication, including rectal corticosteroids, high potency topical corticosteroids and systemic steroids within 28 days prior to randomization.
  • Receipt of blood products within 30 days prior to enrollment (Visit 1).
  • Receipt of any investigational non-biologic product within 30 days or 5 half-lives prior to Visit 1.
  • History of alcohol or drug abuse within the past year, which may compromise the study data interpretation as judged by Investigator or Study Physician.
  • Subjects who in the opinion of the investigator or qualified designee have evidence of active tuberculosis (TB), either treated or untreated.
  • Scheduled in-patient hospitalization or surgical procedure during the course of the study.
  • Asthma as a primary or main diagnosis according to the Global Initiative for Asthma (GINA, guidelines or other accepted guidelines. Subjects with a past medical history of asthma (e.g. childhood or adolescence) may be included.
  • The male partner of someone who may become pregnant during the course of the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02833480

Layout table for location contacts
Contact: Lynda Lazosky 604-682-2344 ext 64884
Contact: Genevieve Rocheleau 604-682-2344 ext 64888

Layout table for location information
Canada, British Columbia
St. Paul's Hospital Recruiting
Vancouver, British Columbia, Canada, V6Z1Y6
Contact: Lynda Lazosky    604-682-2344 ext 64884   
Principal Investigator: Don Sin, MD         
Sub-Investigator: Van Eeden Stephanus, MD         
Sub-Investigator: Leung Janice, MD         
Sub-Investigator: Shaipanich Tawimas, MD         
BC Cancer Agency Recruiting
Vancouver, British Columbia, Canada
Contact: Amy English   
Principal Investigator: Stephen Lam, MD         
Sub-Investigator: Eve-lea Beaudoin, MD         
Sponsors and Collaborators
University of British Columbia
Layout table for investigator information
Principal Investigator: Don Sin, MD St. Paul's Hospital

Layout table for additonal information
Responsible Party: Don Sin, Principle Investigator, University of British Columbia Identifier: NCT02833480     History of Changes
Other Study ID Numbers: H14-02277
First Posted: July 14, 2016    Key Record Dates
Last Update Posted: May 13, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Formoterol Fumarate
Budesonide, Formoterol Fumarate Drug Combination
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Fluticasone-Salmeterol Drug Combination
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Dermatologic Agents
Anti-Allergic Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Hormones, Hormone Substitutes, and Hormone Antagonists